Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease whereby the number of diagnosed patients rises by 3–4% each year creating an ever-expanding social, medical and financial burden. Symptoms such as rigidity, postural instability and bradykinesia are due to diminished levels of dopamine within the brain. More specifically dopamine cell bodies are located in the substantia nigra (SN) and dopamine is released in the striatum. Motor dysfunction becomes evident with a 70–80% loss of dopamine in the striatum. The cause of PD is currently unknown and hence most treatments are aimed at minimizing symptoms not preventing the cause. However, it is known that metabolic status, more specifically calorie restriction is neuroprotective in PD (Bayliss and Andrews, 2013).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
